Dexcom stock received a raised price objective and rating restatement from analysts, accompanied by SEC filings.
1 report, 1 independent
Updated Sep 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dexcom stock received a raised price objective and rating restatement from analysts, accompanied by SEC filings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Dexcom
company that develops, manufactures and distributes continuous glucose monitoring systems
-
Citigroup
American investment bank and financial services corporation
-
Royal Bank of Canada
financial institution in Canada
Related events
- Financial institutions, including Royal Bank of Canada and Citigroup, raised price objectives and lifted target prices for Crown.
- TD Cowen issued a buy rating and price target for Dexcom on October 9, 2026.
- MarketBeat reports on the stock rating for Diversified Healthcare Trust, which is listed on Nasdaq, following a target price raise by Royal Bank of Canada.
- Royal Bank of Canada reiterated an outperform rating on Alfa Laval shares.
- Prudential plc received a reiterated buy rating and price objective from financial firms, including Jefferies Financial Group, as of September 4, 2026.